IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis

被引:75
作者
Emadi, S
Clay, D
Desterke, C
Guerton, B
Maquarre, E
Charpentier, A
Jasmin, C
Le Bousse-Kerdilès, MC
机构
[1] INSERM, Andre Lwoff Inst, Hop Paul Brousse, Unit 602, F-94800 Villejuif, France
[2] Arizona State Univ, Dept Chem & Mat Engn, CME, Tempe, AZ 85287 USA
[3] St Vincent Hosp, Inst Catholique Lille, Grp Hosp, Hematol Lab, Lille, France
关键词
D O I
10.1182/blood-2003-12-4415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloproliferation, myelofibrosis, and neoangiogenesis are the 3 major intrinsic pathophysiologic features of myeloid metaplasia with myelofibrosis (MMM). The myeloproliferation is characterized by an increased number of circulating CD34(+) progenitors with the prominent amplification of dystrophic megakaryocytic (MK) cells and myeloid metaplasia in the spleen and liver. The various biologic activities of interleukin 8 (IL-8) in hematopoietic progenitor proliferation and mobilization as well as in neoangiogenesis prompted us to analyze its potential role in MMM. We showed that the level of IL-8 chemokine is significantly increased in the serum of patients and that various hematopoietic cells, including platelets, participate in its production. In vitro inhibition of autocrine IL-8 expressed by CD34(+) cells with either a neutralizing or an antisense anti-IL-8 treatment increases the proliferation of MMM CD34(+)-derived cells and stimulates their MK differentiation. Moreover, addition of neutralizing anti-IL-8 receptor (CXC chemokine receptor 1 [CXCR1] or 2 [CXCR2]) antibodies to MMM CD34(+) cells cultured under MK liquid culture conditions increases the proliferation and differentiation of MMM CD41(+) MK cells and restores their polyploidization. Our results suggest that IL-8 and its receptors participate in the altered MK growth that features MMM and open new therapeutic prospects for this still incurable disease. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:464 / 473
页数:10
相关论文
共 59 条
[1]   INTERLEUKIN-8 AND THE CHEMOKINE FAMILY [J].
BAGGIOLINI, M ;
LOETSCHER, P ;
MOSER, B .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1995, 17 (02) :103-108
[2]   Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines [J].
Barosi, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2954-2970
[3]   Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Viarengo, G ;
Pecci, A ;
Rosti, V ;
Piaggio, G ;
Marchetti, M ;
Frassoni, F .
BLOOD, 2001, 98 (12) :3249-3255
[4]   A practical approach to multicolor flow cytometry for immunophenotyping [J].
Baumgarth, N ;
Roederer, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 243 (1-2) :77-97
[5]  
BERLIN NI, 1975, SEMIN HEMATOL, V12, P339
[6]   Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis? [J].
Bilhou-Nabéra, C ;
Brigaudeau, C ;
Clay, D ;
Andrieux, J ;
Lai, JL ;
Brouty-Boyé, D ;
Vignon, C ;
Gharbi, MJ ;
Le Bousse-Kerdilès, MC ;
Praloran, V .
BLOOD, 2003, 102 (04) :1551-1552
[7]   Involvement of interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: Evidence from mice lacking the murine IL-8 receptor homologue [J].
Broxmeyer, HE ;
Cooper, S ;
Cacalano, G ;
Hague, NL ;
Bailish, E ;
Moore, MW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (05) :1825-1832
[8]  
BROXMEYER HE, 1993, J IMMUNOL, V150, P3448
[9]  
Castro-Malaspina H, 1984, Prog Clin Biol Res, V154, P307
[10]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2